Bristol-Myers Squibb Co

• Bristol Myers Squibb stock gained momentum ahead of major medical conference presentations. • Analysts upgraded targets following strong clinical pipeline updates and commercial growth assets. • The company reported $48.19B annual revenue and $7.05B net profit.

• Moderna shares declined as investors engaged in profit-taking following recent gains. • Wall Street analysts highlighted valuation friction due to unprofitability and high cash burn. • The company reported an annual revenue of $1.94B and a net loss.

• Bristol-Myers Squibb stock fell despite positive Phase 3 clinical trial results. • RYZ101 met its endpoint, while admilparant showed mixed efficacy at different doses. • Technical indicators show a sell signal with an RSI of 29.182.

• Leerink Partners downgraded Bristol-Myers Squibb and cut its price target. • Approaching patent cliffs for Eliquis and Opdivo threaten future revenues. • U.S. Medicare price negotiations create broader sector policy headwinds.

• ImmunityBio rallied due to strong commercial momentum for its immunotherapy ANKTIVA. • Wall Street analysts maintain a bullish consensus with an average price target of $12.75. • The company reported $113.29M in annual revenue and a net loss of $351.40M.

• United Therapeutics executed an accelerated share repurchase agreement to complete its buyback program. • The FDA accepted filings for nebulized Tyvaso and ralinepag for regulatory review. • The company reported an annual revenue of $3.18B and net profit of $1.33B.